Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission
      QxMD      Google Scholar   
Citation:
Cancer vol 120 (7) 1010-1017
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10 CA047577, U10 CA032291, CA33601, P50 CA140158, U10 CA035091, U10 CA180861, U10 CA077658, U10 CA035279, U10 CA045808, U10 CA031946, U10 CA033601, U10 CA077597, U10 CA059518, U10 CA035421, U10 CA045418, U10 CA077440, U10 CA037447, U10 CA101140, UG1 CA189850, U10 CA041287, U10 CA035113, U10 CA047559, U10 CA180882, P30 CA016058, U10 CA074811, U10 CA180867, U10 CA180838, U10 CA047642, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                                   
Networks:
 
Study
CALGB-19808
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
acute myeloid leukemia, recombinant interleukin-2, phase 3, immunotherapy, adjuvant therapy